Moderna reports surprise profit on higher-than-expected COVID vaccine sales
Moderna reported a surprise third-quarter profit on Thursday, driven by cost cutting and higher-than-expected sales of its ...
Could vaccine for winter vomiting bug be near?
There is currently no licensed vaccine for norovirus – commonly known as the winter vomiting bug – but are scientists getting closer to finally finding a jab that works? Volunteers are being recruited ...
Cautious Outlook on Moderna: Declining Vaccine Demand and Strategic Challenges Prompt Sell Rating
Leerink Partners analyst Mani Foroohar assigned a Sell rating on Moderna (MRNA – Research Report) on November 7 and set a price target of ...
GlobalData on MSN2d
Moderna’s mRESVIA vaccine gains Health Canada approval
Moderna has received Health Canada's approval for its respiratory syncytial virus messenger ribonucleic acid (mRNA) vaccine ...
Moderna Stock Gains on Better-Than-Expected Covid-19 Vaccine Sales
Moderna shares jumped after the biotechnology company reported higher-than-expected sales of its Covid-19 vaccine and backed ...
Canada approves Moderna's RSV vaccine for adults aged 60 and older
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
FiercePharma6d
Moderna disappoints in RSV debut, squares up with Pfizer in COVID-19 vaccine sales
Days after Pfizer and BioNTech reported surprisingly strong sales of their updated COVID-19 vaccines, Moderna has done the ...
Inside Moderna’s Tech-Driven Culture: Insights From CIO Brad Miller
Brad Miller, Moderna's CIO, has driven technology innovation to help drive continued gains for the roughly $7 billion revenue ...
Moderna's Q3 Earnings Beat Overshadowed By Vaccine Demand Slowdown And Market Share Concerns, Analysts Warn
Moderna's stock faces a decline as analysts lower the price target to $90, citing weaker vaccine demand and concerns over ...
BioSpace6d
Moderna Gets Better-Than-Expected Q3 COVID-19 Vaccine Sales, but RSV Shot Disappoints
While Moderna’s Spikevax beat Wall Street estimates in the third quarter, William Blair analyst Myles Minter in a Thursday ...
Canada approves Moderna's RSV vaccine for those age 60 and older, company says
Moderna said on Friday Canada's health regulator has approved its vaccine for respiratory syncytial virus in adults 60 years ...
Medpage Today on MSN2d
Which High-Risk Patients Should Get the RSV Vaccine?
The CDC recommends a single dose of any FDA-approved respiratory syncytial virus (RSV) vaccine for all adults ages 75 years ...